Suchergebnisse - "Potter, Nicola"

PubPharm (39)

1

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Russell, N. | Wilhelm-Benartzi, C. | Othman, J. | +117

2

Post induction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

enthalten in: Blood | 2024

von Othman, J. | Potter, N. | Ivey, A. | +17

3

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy

enthalten in: Blood | 2024

von Othman, J. | Tiong, I. | O'Nions, J. | +33

CommentIn: Blood. 2024 Jan 25;143(4):296-298. - PMID 38270942

4

Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML

enthalten in: Blood advances | 2024

von Jimenez-Chillon, C. | Othman, J. | Taussig, D. | +29

5

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

enthalten in: Leukemia | 2023

von Othman, J. | Potter, N. | Mokretar, K. | +35

6

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS : the UK NCRI AML19 trial

enthalten in: Blood advances | 2023

von Othman, J. | Wilhelm-Benartzi, C. | Dillon, R. | +19

7

Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study

enthalten in: Blood advances | 2023

von Scott, S. | Dillon, R. | Thiede, C. | +8

8

Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

enthalten in: Blood | 2022

von Loo, S. | Dillon, R. | Ivey, A. | +17

9

Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR) : Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial

enthalten in: BMC cancer | 2022

von Dillon, R. | Maycock, S. | Jackson, A. | +14

10

Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial

enthalten in: BMC cancer | 2022

von Dillon, R. | Maycock, S. | Jackson, A. | +14